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Abstract
A continuous infusion of a single high dose of dobutamine has been, recently, suggested as a simple
and effective protocol of stress echocardiography. The present study assesses the feasibility, safety,
and tolerability of an accelerated dobutamine stress protocol performed in patients with suspected
or known coronary artery disease. Two hundred sixty five consecutive patients underwent
accelerated dobutamine stress echocardiography: the dobutamine was administered at a constant
dose of 50 μg/kg/min for up to 10 minutes. The mean weight-adjusted cumulative dose of
dobutamine used was 330 ± 105.24 μg/kg. Total duration of dobutamine infusion was 6.6 ± 2.1 min.
Heart rate rose from 69.9 ± 12.1 to 123.1 ± 22.1 beats/min at peak with a concomitant change in
systolic blood pressure (127.6 ± 18.1 vs. 167.6 ± 45.0 mmHg). Dobutamine administration
produced a rapid increase in heart rate (9.4 ± 5.9 beats/min2). The side effects were similar to those
described with the standard protocol; the most common were frequent premature ventricular
complexes (21.5%), frequent premature atrial complexes (1.5%) and non sustained ventricular
tachycardia (1.5%); among non cardiac symptoms the most frequent were nausea (3.4%), headache
(1.1%) and symptomatic hypotension (1.1%). No major side effects were observed during the test.
Our data demonstrate that a continous infusion of a single high dose of dobutamine is a safe and
well tolerated method of performing stress echocardiography in patients with suspected or known
coronary artery disease. This new protocol requires the administration of lower cumulative
dobutamine dose than standard protocol and results in a significant reduction in test time.
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Background
Dobutamine stress echocardiography (DSE) is commonly
used to assess the extent, location, and severity of coro-
nary artery disease (CAD) and myocardial viability [1-6].
The duration and infusion dose of dobutamine for the
assessment of myocardial ischemia and viability has been
studied extensively [7-10]. Currently, in patients with sus-
pected or known CAD, most laboratories use stepwise
increments of dobutamine at 3-minute intervals, which
has evolved from the commonly used exercise treadmill
protocols. However, steady-state dobutamine levels dur-
ing dobutamine infusion are not obtained for up to 10
minutes [5,7,11]. Consequently, the full effect of any infu-
sion rate of dobutamine is not obtained before the dob-
utamine dose has advanced to the next level [12] and
plasma dobutamine concentrations increase rapidly and
non-linearly during the test [1,13,14]. Furthermore, previ-
ous studies have shown that patients treated with beta-
adrenergic antagonists frequently fail to reach target heart
rate [15,16]. In these patients, the addition of atropine has
been reported to improve the sensitivity of DSE by
increasing the heart rate response [17]. Therefore, a con-
tinuous infusion of a single high dose of dobutamine has
been suggested as a simple and effective protocol of DSE
[1,18]. The present study assesses the feasibility, safety,
and tolerability of an accelerated dobutamine stress pro-




Between March 2002 and October 2007, at San Camillo
Hospital, we prospectively enrolled 265 consecutive
patients (mean age 63.3 ± 11.6; males 185). All patients
underwent ADSE. Demographic and clinical characteris-
tics of patients are reported in Table 1.
Indications for ADSE included evaluation of angina (n =
55), atypical chest pain (n = 22), ECG uninterpretable
ECG (n = 15), chest pain in hypertensive patients (n = 11),
risk stratification after myocardial infarction (n = 180),
follow-up of PTCA (percutaneous transluminal coronary
angioplasty) (n = 113) or CABG (coronary artery bypass
grafting) (n = 20), preoperative risk assessment in non car-
diac surgery (n = 3) and miscellaneous reasons (n = 16).
Patients were on therapy, if indicated, including a drug
combination of β-blockers, long-acting nitrates, calcium
antagonists, others (diuretics, aspirin, statins, ace inhibi-
tors). (Table 1).
Whenever possible or indicated, beta-adrenergic antago-
nists were withheld for at least 72 h before stress echocar-
diography. Informed consent was obtained from all
patients.
Dobutamine Accelerated infusion protocol
Dobutamine was administered at a constant dose of 50
μg/kg/min for up to 10 minutes. All dobutamine stress
tests were performed under continuous 12-lead electro-
cardiographic (ECG) and non-invasive blood pressure
monitoring. After obtaining rest heart rate, blood pressure
and left ventricular two-dimensional echocardiographic
images, the dobutamine infusion was initiated. Diagnos-
tic endpoints of the test were:
positive echocardiogram(new onset wall motion abnor-
malities or worsening of baseline dissinergy); achieve-
Table 1: Clinical characteristics of 265 patients
Clinical parameters n %
Age (yrs) 63.3 ± 11.6
Male sex 185 69.8
History
Hypertension 142 53.6
Diabetes mellitus 51 19.2
Dyslipidemia 116 43.8
Cigarette smoker 54 20.4
Previous MI 185 69.8
Previous CABG 19 7.2
Previous PTCA 112 42.3
Medication
β-blockers 77 29.1
Calcium channel blockers 72 27.2
Nitrates 58 21.9
Other 247 93.2
Values are expressed as mean ± SD or number (%) of patients unless otherwise stated.
CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty;MI, myocardial infarction.Cardiovascular Ultrasound 2007, 5:40 http://www.cardiovascularultrasound.com/content/5/1/40
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ment of 85% of maximal predicted heart rate (220 - age);
severe chest pain and/or diagnostic ST-segment changes.
The test was stopped without diagnostic endpoints for:
Intolerable symptoms; hypertension(systolic blood pres-
sure > 220 mmHg, diastolic blood pressure > 120
mmHg); hypotension (> 30 mmHg fall of blood pres-
sure); supraventricular arrhythmias (supraventricular
tachycardia or atrial fibrillation); or ventricular arrhyth-
mias (ventricular tachycardia; frequent, polymorphous,
premature ventricular beats). Dobutamine infusion was
discontinued after 10 minutes or for 1 of the end points
used in the standard protocol.
Echocardiographic analysis
Echocardiographic images were acquired at rest and dur-
ing stress and recovery. Echocardiograms were recorded
on videotapes and were also digitized on optical disk and
displayed side by side in quad-screen format to facilitate
comparison of images. The left ventricular wall was
divided into 16 segments and scored using a 4-point scale,
where 1 = normal, 2 = hypokinesia, 3 = akinesia, and 4 =
dyskinesia [19]. Wall motion score index was derived by
dividing the sum of individual score of the 16 segments by
16. The interpretation of images was performed by 2 expe-
rienced observers without knowledge of the patients' clin-
ical data. In case of disagreement, a majority decision was
achieved by a third observer. Ischemia was defined as new
or worsening wall motion abnormalities.
Electrocardiographic analysis
Electrocardiographic changes were considered to be
ischemic if an ST-segment shift ≥ 0.1 mV from baseline at
80 milliseconds after the J point occurred in at least 2 con-
tiguous leads (in the absence of Q waves). In the case of
right bundlebranch block, the ST-segment shift was con-
sidered to be significant when it also occurred in leads V5
and V6. Electrocardiographic changes were not taken as
criteria for positivity of the test in the absence of induced
new wall motion abnormalities. However, the develop-
ment of ST-segment depression ≥ 2 mm or ST-segment
elevation  ≥ 1.5 mm was considered to be significant
enough for interruption of the test. In patients with LBBB,
pre-existing ST-segment depression ≥ 0.1 mV or paced
rhythm as well as in patients taking digitalis or
antiarrhythmic medications, electrocardiographic
changes were considered nondiagnostic.
Statistical analysis
Values were expressed as the mean ± SD for continuous
variables and as frequency and percentage for categorical
variables. All data were analyzed by using SPSS 15.0 statis-
tical software for Windows.
Results
Dobutamine doses and times of infusion (Table 2)
The mean weight-adjusted cumulative dose of dob-
utamine used was 330 ± 105.24 μg/kg. Total duration of
dobutamine infusion with ADSE was 6.6 ± 2.1 min.
Hemodynamic response (Table 2)
Heart rate rose from 69.9 ± 12.1 to 123.1 ± 22.1 beats/min
at peak with a concomitant change in systolic blood pres-
sure (127.6 ± 18.1 vs. 167.6 ± 45.0 mmHg).
Dobutamine administration produced a rapid increase in
heart rate (9.4 ± 5.9 beats/min2).
Target heart rate was achieved in 169 out of 265 (63.8%)
patients. Fifty three out of 96 (55%) patients without sub-
optimal chronotropic response were on therapy.
Pharmacologic stress echocardiography and 
electrocardiographic results
Wall motion abnormalities were present at baseline in
114 (43%) patients. The test resulted positive in 61
Table 2: Hemodynamic data of patients during stress echocardiography
Hemodynamic and stress test variables mean ± SD
Heart rate (beats/min)
Rest 69.9 ± 12.1
Peak stress 123.1 ± 22.1
Systolic blood pressure (mm Hg)
Rest 127.6 ± 18.1
Peak stress 136.3 ± 24.5
Rate-pressure product/100 (mm Hg/min)
Rest 89.9 ± 22.8
Peak stress 167.6 ± 45.0
Dobutamine cumulative dose (μg/kg) 330 ± 105.2
Stress time (min) 6.6 ± 2.1
Target heart rate (%) 169 (63.8%)
Heart rate acceleration (beats/min2) 9.4 ± 5.9
Values are expressed as mean ± SD.Cardiovascular Ultrasound 2007, 5:40 http://www.cardiovascularultrasound.com/content/5/1/40
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patients because of the occurrence of new or worsening
wall motion abnormalities. Ischemic electrocardiographic
changes occurred in 68 (25.7%) patients.
β-block
Only in 35 patients (13%) the administration of β-block-
ers at the end of the test was necessary.
Safety and feasibility
No major side effects were observed during the test. Minor
side effects are listed in Table 3.
Out of these effects the most frequent observed were nau-
sea and PVCs.
Urination urgency was another side effect, never described
before, frequently observed during the test (up to 30%).
To obviate this problem, patients were kindly invited to
urinate before beginning the test.
Discussion
Continuous high dose dobutamine stress echocardogra-
phy is a new protocol to add to those in use in all echocar-
dographic laboratories. Other studies using an accelerated
dobutamine infusion protocol have been reported [20-
22]. In a previous study, Burger et al. using the same ADSE
protocol, enrolled a smaller sample size of patients with
suspected coronary artery disease and demonstrated that
this protocol is safe, feasible and useful [1]. Our data con-
firm these results. Furthermore, our study showed that, in
comparison with standard protocols, this new protocol
required the administration of lower cumulative dob-
utamine dose. A significant reduction in test duration was
also demonstrated [23-26]. Therefore, ADSE can be pro-
posed as a useful test in busy laboratories with high vol-
ume of activity for the diagnostic imaging of myocardial
ischemia in some subgroups of patients. However we rec-
ommend physicians to chose the most suitable test for
each single patient.
In this preliminary experience, we demonstrated that the
hemodynamic response is good and comparable with that
found in our Echo-lab using the standard protocol.
This protocol did not consider atropine co-administration
which represents the state of the art dosage regimen
needed to optimise the diagnostic accuracy of the test.
Nevertheless, target heart rate achievment was similar to
that reported in large, multicenter studies using dob-
utamine and atropine [23-26].
The advantages of not employing atropine during stress
were: reduced test time, reduced incidence of an unpleas-
ant dry mouth, improved rate of performing diagnostic
test in patients with narrow angle glaucoma, myasthenia
gravis, obstructive uropathy or obstructive gastrointestinal
disorders, reduced incidence of hypotension.
The ADSE protocol is a safe and well-tolerated method of
performing stress echocardiography in patients with sus-
pected or known coronary artery disease. Furthermore,
Table 3: Adverse effects observed during accelerated dobutamine stress echocardiography
Adverse effects n %
Symptoms 13 4.9
Nausea 9 3.4






General disconfort 1 0.4
Arrhythmias 64 24.2
Atrial fibrillation and flutter 2 0.75
PACs (six or more per minute) 4 1.5
Supraventricular tachycardia 1 0.4
Junctional rhythm 0 0
PVCs (six or more per minute) 57 21.5
NSVT 4 1.5
SVT 0 0
Second-degree AV block 1 0.4
Third-degree AV block 0 0
Bundle branch block. 3 1.1
Others 3 1.1
PACs, premature atrial complexes; PVCs, premature ventricular complexes; N/SVT, Non/sustained ventricular tachycardia.Cardiovascular Ultrasound 2007, 5:40 http://www.cardiovascularultrasound.com/content/5/1/40
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side effects were similar to those described with the stand-
ard protocol [23-28].
Limits
Uncommon side effects occurring during dobutamine
stress echocardiography protocol need a larger sample
size and a multicenter experience to be better evaluated, as
demonstrated by EPIC- EDIC studies [27,29].
Our study represents the experience of a single centre,
although a high flow and specialised one which cooper-
ates with other institutional institutions in performing
EPIC and EDIC studies and meets quality control require-
ments for stress echocardiographic readings.
This protocol is useful to evaluate myocardial ischemia
although in the first 2 minutes it would be possible to
study myocardial viability, since the dose of dobutamine
corresponds approximately to the 10–20 μg/kg/min of the
standard protocol.
The diagnostic accuracy and the prognostic power of
ADSE was not assessed in this preliminary work. In the
near future we shall evaluate these endpoints using coro-
nary angiography for the anatomical assessment of coro-
nary artery disease and myocardial scintigraphy, for the
functional evaluation of inducible ischemia and long
term clinical follow up data for the study of cardiac events.
Conclusion
The ADSE is a new protocol using a continuous single
high dose of dobutamine. Such protocol is a safe and well
tolerated method of studying patients with known or sus-
pected CAD that, using a low cumulative dobutamine
dose, achieves target heart rate in short time, without co-
administration of atropine.
Further investigation will be necessary to confirm our
results and determine diagnostic accuracy and prognostic
power of the test.
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